Resistance against natural killer cell cytotoxicity: Analysis of mechanisms

Scandinavian Journal of Immunology

Volumn 64, Issue 4, 2006, Pages 444-449

  Hasenkamp, J ^a   Borgerding, A ^a   Wulf, G ^a   Uhrberg, M ^b   Jung, W ^a   Dingeldein, S ^a   Truemper, L ^a   Glass, B ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; HLA ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR;

ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN INTERACTION; SENSITIVITY ANALYSIS; TARGET CELL;

CELL LINE, TUMOR; CLONE CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; GRANZYMES; HLA-A3 ANTIGEN; HUMANS; IMMUNITY, NATURAL; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA; RECEPTORS, IMMUNOLOGIC; SERINE ENDOPEPTIDASES;

EID: 33748790374     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01803.x     Document Type: Article

References (35)

1. Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 1995;7:704-10.
2. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333-9.
3. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
4. Giebel S, Locatelli F, Lamparelli T et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003;102:814-9.
5. Beelen DW, Ottinger HD, Ferencik S et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005;105:2594-600.
6. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-7.
7. Lehmann C, Zeis M, Schmitz N, Uharek L. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 2000;96:594-600.
8. Bladergroen BA, Meijer CJ, ten Berge RL et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 2002;99:232-7.
9. Medema JP, de Jong J, Peltenburg LT et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001;98:11515-20.
10. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002;20:217-51. Epub @ 2001 Oct 4.:217-251.
11. Gunturi A, Berg RE, Forman J. The role of CD94/NKG2 in innate and adaptive immunity. Immunol Res 2004;30:29-34.
12. Bottino C, Castriconi R, Pende D et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003;198:557-67.
13. Pende D, Spaggiari GM, Marcenaro S et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005;105:2066-73.
14. Moretta A, Bottino C, Vitale M et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
15. Karre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol 2002;55:221-8.
16. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-8.
17. Burns LJ, Weisdorf DJ, DeFor TE et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003;32:177-86.
18. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
19. Classen CF, Falk CS, Friesen C, Fulda S, Herr I, Debatin KM. Natural killer resistance of a drug-resistant leukemia cell line, mediated by up-regulation of HLA class I expression. Haematologica 2003;88:509-21.
20. Avril T, Jarousseau AC, Watier H et al. Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism. J Immunol 1999;162:5902-9.
21. Komatsu F, Yoshida S. Characteristics of human T-lymphotropic virus type-1 (HTLV-1)-infected cell line MT-2, which is not killed by a natural killer cell line NK-92 but is killed by lymphokine-activated killer cells. Oncol Res 1999;11:213-8.
22. Betser-Cohen G, Katz G, Gonen-Gross T et al. Reduced KIR2DL1 recognition of MHC Class I molecules presenting phosphorylated peptides. J Immunol 2006;176:6762-9.
23. Uhrberg M, Valiante NM, Shum BP et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997;7:753-63.
24. Uhrberg M, Parham P, Wernet P. Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 2002;54:221-9.
25. Lehmann C, Glass B, Zeis M, Schmitz N, Uharek L. Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity. Cancer Immunol Immunother 1999;48:209-13.
26. Sivori S, Pende D, Bottino C et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999;29:1656-66.
27. Pende D, Parolini S, Pessino A et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190:1505-16.
28. Vitale M, Bottino C, Sivori S et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998;187:2065-72.
29. Vitale M, Falco M, Castriconi R et al. Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol 2001;31:233-42.
30. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 2000;21:228-34.
31. Moretta A, Bottino C, Vitale M et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996;14:619-48.
32. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990;11:237-44.
33. Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A. Human NK-cell receptors. Immunol Today 2000;21:420-2.
34. Komatsu F, Kajiwara M. Enhancement of tumor cell lysis by natural killer cells after blocking of HLA-monomorphic determinant using F(ab′)2 fragment of W6/32. Cancer Detect Prev 1998;22:168-75.
35. Koh CY, Blazar BR, George T et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001;97:3132-7.